Ocular Therapeutix (OCUL) Revenue (2014 - 2026)

Ocular Therapeutix's Revenue history runs 13 years deep, the most recent figure standing at $10.8 million for Q1 2026.

• On a quarterly basis, Revenue rose 0.81% year-over-year to $10.8 million in Q1 2026; TTM through Mar 2026 was $52.0 million, a 12.76% decrease from a year earlier, with the FY2025 full-year figure at $52.0 million, down 18.47% from the prior year.
• Revenue eased to $10.8 million in Q1 2026 per OCUL's latest filing, from $13.2 million in the prior quarter.
• Across five years, Revenue topped out at $17.1 million in Q4 2024 and bottomed at $10.7 million in Q1 2025.
• The 5-year median for Revenue is $14.1 million (2022), against an average of $13.9 million.
• Across the five-year window, Revenue jumped 79.61% in 2022 and retreated 27.59% in 2025, its largest moves.
• Year by year, Revenue stood at $14.1 million in 2022, then grew by 5.16% to $14.8 million in 2023, then grew by 15.41% to $17.1 million in 2024, then dropped by 22.43% to $13.2 million in 2025, then slipped by 18.6% to $10.8 million in 2026.
• Per Business Quant, the three latest OCUL Revenue figures stand at $10.8 million (Q1 2026), $13.2 million (Q4 2025), and $14.5 million (Q3 2025).